
News|Articles|July 1, 2004
TNF inhibitor use associated with granulomatous infectious disease; infliximab poses greatest risk
Tumor necrosis factor (TNF) antagonists increase the risk of granulomatous infectious disease, including tuberculosis, according to a study-the largest of its kind to date-published in the journal Clinical Infectious Diseases. The risk of infection was 3.25-fold greater among patients who received infliximab (Remicade, Centocor) than among those who received etanercept (Enbrel, Wyeth/Amgen), the study found.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA issues third rejection of bevacizumab to treat wet AMD
2
Predictions for 2026 from Lucille Accetta, RPh, M.P.H., MBA, A.J. Loiacono and Allan Pannier, Pharm.D. MBA
3
Top 5 articles from the MHE print publication
4
Predictions for 2026 from Tracy Baroni Allmon, Sharon Faust, Mike Kolodij, and others
5




















































